NCT01804933

Brief Summary

Although deep anesthesia can produce skeleton muscle relaxation,unnecessary deep anesthesia often had adverse cardiac effects and was related to 2-year mortality in cancer patients.The use of muscle relaxants allowed the depth of anesthesia to be optimized.However, for many anesthesiologists,in fear of residual postoperative neuromuscular blockade,intraoprative administration of muscle relaxants had to be minimized in spite of poor surgical conditions. This study, however, is designed to test the hypothesis that profound neuromusclular blockade reduces muscle trauma caused by self-retaining retractor and thus cut down postoperative analgesic requirement.On the other hand,profound muscle relaxation can decrease postoperative diaphragmatic dysfunction and abdominal muscle trauma, which can improve postoperative pulmonary function.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
72

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jul 2012

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2012

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

March 4, 2013

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 5, 2013

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2013

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2013

Completed
Last Updated

March 5, 2013

Status Verified

March 1, 2013

Enrollment Period

1 year

First QC Date

March 4, 2013

Last Update Submit

March 4, 2013

Conditions

Keywords

profound muscle relaxationmuscle traumapostoperative analgesic demandpostoperative pulmonary function

Outcome Measures

Primary Outcomes (1)

  • degree of muscle trauma

    serum CK

    72h postoperatively

Secondary Outcomes (1)

  • postoperative analgesic requirement

    7days postoperatively

Other Outcomes (1)

  • postoperaive pulmonary function

    3days postoperatively

Study Arms (3)

conventional neuromuscular blockade

NO INTERVENTION

No rocuronium will be administered intraoperatively unless there is surgeons' complain or patients movement

optimal neuromuscular blockade

ACTIVE COMPARATOR

Rocuronium dose will be infused to maintain depth of NMB at TOF count 1 intraoperatively

Drug: profound neuromuscular blockade

profound neuromuscular blockade

EXPERIMENTAL

Rocuronium dose will be infused to maintain a depth of NMB to PTC 1\~2 intraoperatively

Drug: profound neuromuscular blockade

Interventions

Rocuronium dose will be infused to maintain a depth of NMB to PTC 1\~2 intraoperatively

optimal neuromuscular blockadeprofound neuromuscular blockade

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ASA 1\~2,scheduled to undergo upper abdominal surgery by midline incision

You may not qualify if:

  • neuromuscular disorder
  • history of malignant hyperthemia
  • allergy to medications used during general anesthesia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, 510080, China

RECRUITING

Study Officials

  • Ying Xiao, MD, PhD

    First Affiliated Hospital, Sun Yat-Sen University

    STUDY DIRECTOR

Central Study Contacts

Ying Xiao, MD,PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

March 4, 2013

First Posted

March 5, 2013

Study Start

July 1, 2012

Primary Completion

July 1, 2013

Study Completion

August 1, 2013

Last Updated

March 5, 2013

Record last verified: 2013-03

Locations